Static Chart CervoMed Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 20:14:34 20/06/2024 BST			5-day change	1st Jan Change
20.82 ^USD	+7.13%		+5.21%	+172.48%

06-11	CervoMed Inc. Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies	CI
05-29	JonesTrading Starts CervoMed With Buy Rating, $70 Price Target	MT

Duration

Period